Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.57 |
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996333 | 0.90 | MME (0.53) | GPR34ACEMMECTSLCTSB | |
| SCHEMBL5967322 | 0.90 | MME (0.53) | GPR34ACEMMECTSLCTSB | |
| SCHEMBL10504767 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BECE1MME | |
| SCHEMBL4144665 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BECE1MME | |
| SCHEMBL4144668 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BECE1MME | |
| SCHEMBL16452927 | 0.87 | CNR2 (0.64) | GPR34ACEALDH1A1ITGB3ITGA2B | |
| SCHEMBL16452918 | 0.85 | CNR2 (0.58) | GPR34ACEALDH1A1ITGB3ITGA2B | |
| SCHEMBL17431819 | 0.83 | GPR34 (0.62) | GPR34ACEALDH1A1ITGB3ITGA2B | |
| SCHEMBL3342648 | 0.83 | PIN1 (0.62) | — | |
| SCHEMBL1458962 | 0.82 | TACR1 (0.56) | ACEITGB3ITGA2BMMECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822698-B2 | Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20130085143-A1 | AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE D'AIX-MARSEILLE (FR) | 2013-04-04 | — | — | US | disclosed |
| EP-2483280-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | Université d'Aix-Marseille (FR) | 2012-08-08 | — | — | EP | disclosed |
| EP-2305688-A1 | Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors | Université de la Méditerranée - Aix-Marseille II (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011036303-A1 | NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085143-A1 | AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY | MET, HGFAC, HRAS | GPR34 3513/4885ACE 3192/4885ALDH1A1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.